$Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant$

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant

Bibliographic Details
Main Authors:	Ashley McEwan, Omali Pitiyarachchi, Nicholas Viiala
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000379

Similar Items

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
by: Juan Chen, et al.
Published: (2023-01-01)

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients
by: Gianmarco Bagnato, et al.
Published: (2024-01-01)

IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine
by: Poorva Vaidya, et al.
Published: (2024-01-01)

P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)
by: F. Ravandi, et al.
Published: (2022-06-01)

MRI findings of nelarabine‐related rhabdomyolysis in a patient with refractory T‐cell acute lymphoblastic leukemia
by: Daiki Mukai, et al.
Published: (2023-08-01)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
by: Kamel Laribi, et al.
Published: (2022-02-01)

PB1871: HIGH RATES OF INFECTION AND RELATED MORALITY FROM VENETOCLAX THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE RETROSPECTIVE STUDY
by: Durga Chandran, et al.
Published: (2023-08-01)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
by: Hyunkyung Park, et al.
Published: (2020-07-01)

Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
by: Seema Naik, et al.
Published: (2024-01-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: Inna Shaforostova, et al.
Published: (2023-08-01)

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
by: Tzu-Ting Chen, et al.
Published: (2024-03-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
by: Xiaohui Gao, et al.
Published: (2023-11-01)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
by: Nina Nguyen, et al.
Published: (2022-10-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma
by: Dalma Deak-Mihaly, et al.
Published: (2021-09-01)

Successful stem cell transplantation after nelarabine, pegylated asparaginase, vincristine, doxorubicin, and prednisone in refractory early T-cell precursor acute lymphoblastic leukemia: A case report
by: Marcela Espinoza, et al.
Published: (2023-05-01)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
by: Gi-June Min, et al.
Published: (2023-10-01)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
by: Taha Al-Juhaishi, et al.
Published: (2022-01-01)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
by: Muhammad Salman Faisal, et al.
Published: (2023-04-01)

457 A Phase I Trial of Tazemetostat and Venetoclax in Relapsed and Refractory non-Hodgkin Lymphoma
by: Erin Mulvey, et al.
Published: (2024-04-01)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
by: Andrea Ceglédi, et al.
Published: (2023-11-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
by: Eyal Lebel, et al.
Published: (2023-03-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report
by: Yili Fan, et al.
Published: (2023-12-01)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
by: S. Chen, et al.
Published: (2022-06-01)

Daratumumab and Nelarabine Treatment as Salvage Therapy for T-Lymphoblastic Lymphoma: A Case Report
by: Gonzalo Castellanos, et al.
Published: (2024-02-01)

VENETOCLAX-BASED THERAPIES IN PEDIATRIC ADVANCED MDS AND RELAPSED/REFRACTORY AML: A MULTICENTER RETROSPECTIVE ANALYSIS
by: Riccardo Masetti, et al.
Published: (2023-12-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Origins of ETP Leukemia
by: Booth, CAG, et al.
Published: (2018)

On the Origin of ETP Leukemias
by: Melania Tesio
Published: (2018-06-01)

Refractory Autoimmune Cytopenias Treated With Venetoclax
by: Max J. Gordon, et al.
Published: (2019-06-01)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
by: Tingting Yang, et al.
Published: (2023-02-01)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
by: Xing-yu Cao, et al.
Published: (2023-12-01)

P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA
by: Sabine Kayser, et al.
Published: (2023-08-01)